Abstract
A patient experienced gastric fundic gland-type hyperplastic polyps, consisting of foveolar epithelium and parietal cells, complicated with chronic bleeding due to long-term treatment with vonoprazan. The patient had progressive anemia, probably caused by bleeding from the polyps. After switching from vonoprazan to a histamine-2 (H2) receptor antagonist, the polyps markedly shrank and the anemia improved. Vonoprazan can produce reversible hyperplastic polyps and anemia. In case of anemia in patients receiving long-term vonoprazan, it is important to consider drug cessation or change to an H2 blocker.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hongo M, Fujimoto K, Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45:618–24.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42:649–63.
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–34.
Kamada T, Yamanaka Y, Matsumoto H, et al. Long-term administration of proton pump inhibitors and morphological change of fundic gland polyps. Endosc Dig. 2015;27:83–92.
Mukai S, Nagata S, Shigita K, et al. Long-term administration of PPI and gastric polyp. Endosc Dig. 2020;32:1172–9.
Takeda T, Asaoka D, Tajima Y, et al. Hemorrhagic polyps formed like fundic gland polyps during long-term proton pump inhibitor administration. Clin J Gastroenterol. 2017;10:478–84.
Tanaka M, Kataoka H, Yagi T. Proton-pump inhibitor-induced fundic gland polyps with hematemesis. Clin J Gastroenterol. 2019;12:193–5.
Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42:1315–26.
Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease. J Gastroenterol. 2021;57:267–85.
Saito M, Koike T, Abe Y, et al. The development of foveolar-type gastric adenocarcinoma during maintenance therapy of vonoprazan for reflux esophagitis. Intern Med. 2021;60:391–6.
Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med. 2020;59:507–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).
Informed consent
Informed consent was obtained from all patients to be included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Goto, C., Okimoto, K., Matsusaka, K. et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol 16, 159–163 (2023). https://doi.org/10.1007/s12328-022-01751-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-022-01751-0